Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated G2 to M transition: Implications for gene therapy

Cancer Research

Volumn 57, Issue 5, 1997, Pages 818-823

  Skladanowski, Andrzej ^a,b   Larsen, Annette K ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; ETOPOSIDE; GYRASE INHIBITOR; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; ETIOLOGY; GENE EXPRESSION; GENE THERAPY; MITOSIS; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE; CELL SURVIVAL; CRICETINAE; DNA FRAGMENTATION; ETOPOSIDE; G2 PHASE; GENE THERAPY; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; MITOSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031029576     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
2. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53 dependent DNA damage response pathway. Mol. Cell. Biol., 14: 1815-1823, 1994.
3. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damuging agents. Cancer Res., 54: 5824-5830, 1994.
4. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancer. Science (Washington DC), 253: 49-52, 1991.
5. Zambetti, G. P., and Levine, A. J. A comparison of the biological activities of wild-type and mutant p53. FASEB J., 7: 855-865, 1993.
6. Michalovitz, D., Halevy. O., and Oren, M. Conditional inhibition of transformation and cell proliferation by a temperature-sensitive mutant of p53. Cell, 62: 671-680, 1990.
7. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin 6. Nature (Lond.), 352: 345-347, 1991.
8. Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. Induction of apoptosis by wild-type p53 in human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
9. Vikhanskaya, F., Erba, E., D'Incalci, M., and Broggi, M. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res., 22: 1012-1017, 1994.
10. Soddu, S., Blandino, G., Scardige, R., Martinelli, R., Rizzo, M. G., Crescenzi, M., and Sacchi, A. Wild-type p53 induces diverse effects in 32D cells expressing different oncogenes, Mol. Cell. Biol., 16: 487-495, 1996.
11. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
12. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1. a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
13. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 Cdk-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
14. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70:923-935, 1992.
15. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
16. Steward, N., Hicks, G. G., Paraskevas, F., and Mowat, M. Evidence for a second cell cycle block at G2/M by p53. Oncogene, 10: 109-115, 1995.
17. Agarwal, M. L., Agarwal, A., Taylor, W. R., and Stark, G. R. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA, 92: 8493-8497, 1995.
18. Guillof, C., Rosselli, F., Krishnaraju, K., Moustacci, E., Hoffman, B., and Liebermann, D. A. p53 involvement in control of G2 exit of the cell cycle: role in DNA-damage induced apoptosis. Oncogene, 10: 2263-2270, 1995.
19. Clarke, A. R., Purdie, A. J., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
20. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74: 957-967, 1993.
21. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Yokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in head and neck cancer cell lines. Cancer Res., 53: 3666-3669, 1993.
22. Biard, D. S. F., Martin, M., Le Rhun, Y., Lefaix, J. L., May, E., and May, P. Concominant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res., 54: 3361-3364, 1994.
23. Fan, S., Smith, M. L., Rivet, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., Jr., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
24. cdc2 kinase in etoposide-induced cell death of Chinese hamster ovary cells. Cancer Res., 50: 3767-3771, 1990.
25. Lock, R. B., Galperina, O. V., Feldhoff, R. C., and Rhodes, L. J. Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells. Cancer Res., 54: 4933-4939, 1994.
26. Lock, R. B., and Stribinskine, L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res., 56: 4006-4012, 1996.
27. Kerr, J. F. R. Winterford, C. M., and Harmon, B. V. Apoptosis, its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
28. Demarcq, C., Bunch, R. T., Creswell, D., and Eastman, A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth & Differ., 5: 983-993, 1994.
29. Skladanowski, A., Benchokroun, Y., Scala, D., Yonish-Rouach, E., and Larscn. A. K. Induction of apoptosis by topoisomerase II inhibitors in M1 myeloid leukemia cells: the influence of p53. Proc. Am. Assoc. Cancer Res., 36: 2653, 1995.
30. Godar, D. E., Miller, S. A., and Thomas, D. P. Immediate and delayed apoptotic cell death mechanisms: UVA versus UVB and UVC radiation. Cell Death Differ., 1: 59-66, 1994.
31. Gorczyca, W., Bruno, S., Darzynkiewicz, R. J., Gong, J., and Darzynkiewicz, Z. DNA strand breaks occurring during apoptosis: their early in situ detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int. J. Oncol., 1: 639-648, 1992.
32. Davies, F. M., Tsao, T. Y., Fowler, S. K., and Rao, P. N. Monoclonal antibodies to mitotic cells. Proc. Natl. Acad. Sci. USA, 80: 2926-2930, 1983.
33. Yonish-Rouach, E., Grunwald, D., Wilder, S., Kimchi, A., May, E., Lawrence, J-J., May, P., and Oren, M. p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol., 13: 1415-1423, 1993.
34. Anderson, H., and Roberge, M. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells. Cell Growth & Differ., 7: 83-90, 1996.
35. Attardi, L. D., Lowe, S. W., Brugarola, J., and Jacks, T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J., 15: 3693-3701, 1996.
36. Lock, R. B. Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide. Cancer Res., 52: 1817-1822, 1992.
37. Okamoto, K., and Beach, D. Cyclin G is a transcriptional target of the p53 tumor supressor protein. EMBO J., 19: 4816-4822, 1994.
38. Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, A., and O'Connor, P. M. UCN-01 : a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst., 88: 956-965, 1996.
39. Yao, S-L., Akhtar, A. J., McKenna, K. A., Bedi, G. C., Sidransky, D., Mabry, M., Ravi, R., Collector, M. I., Jones, R. J., Shakis, S. J., Fuchs, E. J., and Bedi, A., Selective radiosensitisation of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat. Med., 2: 1140-1143, 1996.